BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17308959)

  • 1. Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.
    Mascarell S; Sarne DH
    Pituitary; 2007; 10(1):95-101. PubMed ID: 17308959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Some issues in the diagnosis and treatment of hyperprolactinemia].
    Jin ZM
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperprolactinemia and prolactinomas.
    Mancini T; Casanueva FF; Giustina A
    Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prolactin-secreting adenoma].
    Brue T; Morange I; Jaquet P
    Rev Prat; 1996 Jun; 46(12):1486-9. PubMed ID: 8881162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
    Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
    Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reversible blindness caused by an invasive prolactinoma].
    Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C
    Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
    Fleseriu M; Lee M; Pineyro MM; Skugor M; Reddy SK; Siraj ES; Hamrahian AH
    J Neurooncol; 2006 Aug; 79(1):41-3. PubMed ID: 16598425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
    Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
    Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperprolactinemia unrelated to prolactinoma].
    Krysiak R; Okopień B
    Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprolactinemia: etiology, diagnosis, and management.
    Mah PM; Webster J
    Semin Reprod Med; 2002 Nov; 20(4):365-74. PubMed ID: 12536359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinomas.
    Glezer A; Bronstein MD
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prolactinoma].
    Glezer A; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prolactinoma treatment status in the cabergoline era].
    Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
    No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.